Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ICU Medical's annualized net income for the quarter that ended in Dec. 2023 was $-69 Mil. ICU Medical's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-229 Mil. Therefore, ICU Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.
The historical rank and industry rank for ICU Medical's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, ICU Medical's highest Return-on-Tangible-Equity was 10.68%. The lowest was -14.26%. And the median was 7.77%.
ICUI's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.87 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
ICU Medical Return-on-Tangible-Equity Historical Data
The historical data trend for ICU Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ICU Medical's Return-on-Tangible-Equity
For the Medical Instruments & Supplies subindustry, ICU Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ICU Medical's Return-on-Tangible-Equity falls into.
ICU Medical Return-on-Tangible-Equity Calculation
ICU Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
ICU Medical (NAS:ICUI) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ICU Medical Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of ICU Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICUI has been successfully added to your 